This is an important finding because the risk of HF increases with a declining eGFR [35]; therefore, these data give confidence in the role of SGLT2 inhibitors in renoprotection as well as in the reduction of incident HF in T2DM. This evidence concerns the gene SLC5A2 and type 2 diabetes mellitus.